Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Xiaflex Closer to Second Indication

By Drug Discovery Trends Editor | June 5, 2012

MALVERN, Pa. (AP) – Auxilium Pharmaceuticals Inc. said its drug Xiaflex worked as a treatment for a condition that causes curvature of the penis and makes sex difficult.

Xiaflex was previously approved in 2010 as a treatment for Dupuytren’s contracture, which causes the tendons of the hand to thicken and shorten and makes the fingers curve inward.

Auxilium is also testing the drug as a treatment for Peyronie’s disease, which is caused by development of scar tissue that can harden and curve the penis. The company said the drug reduced that abnormal curvature in two late-stage clinical trials.

Auxilium said it plans to file for marketing approval of Xiaflex as a treatment for Peyronie’s disease by the end of 2012. The company said it believes the condition is diagnosed in 65,000 to 120,000 men per year, and 5,000 to 6,500 people per year are treated with surgery or injectable therapies for the condition. It said Xiaflex would be the first biologic therapy for Peyronie’s disease.

The most common side effects in the trial were bruising, pain and swelling at the injection site. Most of those side effects cleared up within two weeks.

The Food and Drug Administration approved Xiaflex in early 2010. Auxilium reported a total of $56.4 million in Xiaflex revenue in 2011 and $14.9 million in the first quarter of 2012. In both periods, that was about 20 percent of the company’s revenue.

Date: June 4, 2012
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE